Peter Dicpinigaitis, MD, professor of medicine at the Albert Einstein College of Medicine, director of the Montefiore Cough Center, and editor-in-chief of LUNG, addresses the lack of approved treatments for chronic cough in the United States, current off-label remedies, and the prospect of future approvals.
Chronic refractory cough suffers from a marked lack of approved treatments in the United States, and the 2 remedies used on an off-label basis—amitriptyline and gabapentin—have adverse effects many patients find intolerable, noted Peter Dicpinigaitis, MD, professor of medicine at the Albert Einstein College of Medicine, director of the Montefiore Cough Center, and editor-in-chief of LUNG.
Transcript
Without any drugs on the market in the United States, how is chronic cough treated?
When I lecture about cough, I spend a lot of time talking about trying to find these underlying treatable causes of cough—because once we get to the stage of refractory chronic cough, we unfortunately do not have any approved treatments for refractory chronic cough. There's never been a chronic cough drug approved in the United States. Hopefully that'll change next year with the approval of gefapixant.
What we have now, unfortunately, at our disposal once we've made the diagnosis of refractory chronic cough, is really just off-label treatments. Narcotics are used, but of course, those are not a very palatable option for what is going to be chronic treatment. So most of us are left with the 2 drugs that are referred to as neuromodulators, trying to suppress this hypersensitive cough reflex that we deal with. Those are an old antidepressant, amitriptyline, and gabapentin.
We use those, but unfortunately in my experience, I've had very little success with these drugs in terms of their efficacy against cough. But oftentimes even if there is a benefit for cough, often the side effects—mainly sedation—are just intolerable to the patient. So we really don't have any good, safe, effective, well-tolerated options for chronic cough, and that's why we're so excited that we have multiple pipeline programs now, which will hopefully render chronic cough drugs in the near future.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More